Ratings CanSino Biologics Inc. Shanghai S.E.

Equities

688185

CNE100004BM0

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
43.3 ^CNY	+4.89%		-2.87%	-41.89%

06-24	Cansino Biologics' Senior Management to Boost Stakeholding	MT
06-10	Indonesia ramps up fight against tuberculosis amid concerns on economic impact	RE

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company is in a robust financial situation considering its net cash and margin position.
The company's share price in relation to its net book value makes it look relatively cheap.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's enterprise value to sales, at 5.27 times its current sales, is high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
CANSINO BIOLOGICS INC.	-41.89%	1.02B	-
CSL LIMITED	+2.97%	94.74B	A-
SAMSUNG BIOLOGICS CO.,LTD.	-4.08%	37.28B	A-
BIOGEN INC.	-13.26%	32.68B	B-
UCB	+74.08%	27.72B	A
BIOMARIN PHARMACEUTICAL INC.	-11.58%	16.19B	C
INCYTE CORPORATION	-1.66%	13.88B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.67%	11.58B	D+
ALTEOGEN INC.	+190.36%	10.92B	D
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-52.61%	9.54B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes